Sunny Xie is the Vice President of Biometrics at Neogene Therapeutics. Before joining Neogene, Sunny served as VP of Biometrics at OncoSec Medical, where he supported the development of strategy and execution of the immune oncology therapy pIL-12 with electroporation in combination with a checkpoint inhibitor. Before OncoSec, Sunny served as the VP of Biometrics at Nektar Therapeutics, where he built up the Biometrics group and supported the development of engineered immune-oncology therapies including pegylated IL-2 from first-in-human to Phase 3 studies in various indications.
Prior to Nektar Therapeutics, Sunny held various development leadership roles in pharmaceutical organizations of different sizes, supporting clinical programs and regulatory interactions in various therapeutic areas.
Sunny received his Bachelor’s degree in Applied Mathematics at Shandong University in China and Master’s degree in Statistics at Sam Houston State University.